Factors Associated With Weight Change After Continuing or Switching to a Doravirine-based Regimen
Open Forum Infectious Diseases · 30.10.2025 · 12 (11)
DOI: 10.1093/ofid/ofaf639 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 20.11.2025. Verfasst von Chloe Orkin und 7 weiteren Autor:innen. Beteiligte Einrichtung: SHARE Collaborative, Blizard Institute, Queen Mary University of London, London, UK. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Factors associated with weight change were examined in phase 3 studies in which adults living with HIV-1 continued or switched to doravirine-based antiretroviral regimens.
Methods
Participants were randomized to first-line therapy with doravirine or darunavir/ritonavir, each given with 2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) (DRIVE-FORWARD) and to doravirine/lamivudine/tenofovir disoproxil fumarate (TDF) or efavirenz/emtricitabine/TDF (DRIVE-AHEAD); after 96 weeks, participants continued (n = 466) or switched to (n = 423) doravirine for 96-week open-label extensions. In DRIVE-SHIFT, virologically suppressed participants on stable antiretroviral therapy were randomized to switch to doravirine/lamivudine/TDF at day 1 or week 24 through week 144 (n = 535). Generalized logistic models were used to analyze factors associated with weight loss (≥5% decrease), stable weight (<5% change), and weight gain (≥5% increase) after continuation or switch.
Results
Most participants who continued or switched to doravirine also received TDF (>74%) and had stable weight (>57%). Weight loss (odds ratio [OR], 6.14) or stable weight (OR, 2.15) was more common in participants of non-Black versus Black heritage after switching to doravirine. More participants switching from weight-suppressive non-nucleoside reverse transcriptase inhibitors versus protease inhibitors experienced weight gain versus weight loss in DRIVE-SHIFT (OR, 0.41) and weight gain versus stable weight in DRIVE-FORWARD and DRIVE-AHEAD (OR, 0.60). No significant association between weight change and prior NRTI use was observed in DRIVE-SHIFT.
Conclusions
Overall, switching to doravirine was weight neutral, although weight change may differ by demographics and weight-suppressive properties of a prior regimen. More research in historically underrepresented groups may help explain these findings. ClinicalTrials.gov NCT02275780, NCT02403674, NCT02397096.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- SHARE Collaborative, Blizard Institute, Queen Mary University of London, London, UK.
- Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Division of Infectious Diseases and Tropical Medicine, Medstar Georgetown University Hospital, Washington, DC, USA.
- MRL Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA.
ORCID-Profile: Chloe Orkin, John R Koethe, Peter Sklar, Rebeca M Plank
Zitieren
APA
Orkin, C., Koethe, J. R., Kumar, P. N., Sklar, P., Xu, Z. J., Plank, R. M., Greaves, W., & Lahoulou, R. (2025). Factors Associated With Weight Change After Continuing or Switching to a Doravirine-based Regimen. Open Forum Infectious Diseases, 12(11). https://doi.org/10.1093/ofid/ofaf639
Vancouver
Orkin C, Koethe JR, Kumar PN, Sklar P, Xu ZJ, Plank RM, et al. Factors Associated With Weight Change After Continuing or Switching to a Doravirine-based Regimen. Open Forum Infectious Diseases. 2025;12(11). doi:10.1093/ofid/ofaf639
BibTeX
@article{Orkin2025,
author = {Orkin, Chloe and Koethe, John R and Kumar, Princy N and Sklar, Peter and Xu, Zhi Jin and Plank, Rebeca M and Greaves, Wayne and Lahoulou, Rima},
title = {Factors Associated With Weight Change After Continuing or Switching to a Doravirine-based Regimen},
journal = {Open Forum Infectious Diseases},
year = {2025},
volume = {12},
number = {11},
doi = {10.1093/ofid/ofaf639}
}
EUVIMED